Moderna's COVID Vaccine Could Be Better Than Pfizer's -- Here's Why Its Stock Isn't
The numbers are in. And they look really good for Moderna (NASDAQ: MRNA).
On Sept. 17, the Centers for Disease Control and Prevention (CDC) released interim data that compared the effectiveness of the three COVID-19 vaccines on the market in the U.S. Moderna's vaccine was found to be 93% effective at preventing hospitalizations, compared to 88% for the vaccine developed by Pfizer (NYSE: PFE) and BioNTech. Johnson & Johnson's COVID-19 vaccine trailed behind both with an effectiveness against hospitalization of 71%.
The effectiveness of Moderna's and Pfizer's vaccines was very close in preventing infection during the first few months after the second dose -- 92% and 91%, respectively. However, after 120 days, the effectiveness for Moderna's vaccine slipped only 1%, while Pfizer's vaccine effectiveness declined by 14%.
Source Fool.com
